Using laser acupuncture to help prevent chronic migraines

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the efficacy and safety of laser acupuncture as an add-on preventive therapy for chronic migraine patients. Participants aged over 20 with a history of chronic migraines will be randomly assigned to receive either laser acupuncture or a sham treatment. The study will evaluate changes in monthly migraine days, medication usage, and psychological assessments over a six-month period, followed by an additional three months for the sham group after receiving the treatment. The goal is to determine if laser acupuncture can effectively reduce migraine frequency and improve overall patient well-being.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients aged above 20 years old and had CM managed pharmacologically, including preventive and/or acute migraine medications, and in addition, those who had refused preventive agent despite recommendation of the neurologist;
* patients who had unsatisfactory effect of current pharmacological treatments, defined as they self-reported
* patients who had a minimum of one-year history of migraine with or without aura.

Exclusion Criteria:

* patients who had received another LA therapy or traditional acupuncture at baseline
* migraine onset after the age of 50
* cognitive or psychological impairment interfering with the participant's ability to receive LA protocol and describe symptoms
* patients with missing data at baseline or during the follow-up period.

Where it's running

• Taichung Veterans General Hospital
  Taichung, Xitun District, Taiwan Recruiting

Study contacts

• Study coordinator: ChiSheng Wang, M.D
• Email: sam7227632@gmail.com
• Phone: +886933375721

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nebulized dexmedetomidine for early chronic migraine

  This study tests whether inhaled dexmedetomidine can lessen central sensitization and help prevent chronification in people with early chronic migraine.

  Recruiting Beni-Suef University · Banī Suwayf · NCT07769255

• i-NEED: New migraine drugs database

  This project will collect real-life data to see how new migraine treatments—anti‑CGRP antibodies, gepants, ditans, and a sumatriptan‑naproxen combo—work and how well adults with episodic or chronic migraine tolerate them.

  Recruiting at 2 sites IRCCS San Raffaele Roma · Milan, Italy and 1 other locations · NCT07103694

• Suppressive Functions of Regulatory T Cells in Migraine

  This study tests whether regulatory T cells can help control migraine-related inflammation in adults with chronic migraine.

  Recruiting University Hospital, Clermont-Ferrand · Clermont-Ferrand · NCT07067112

• Comparing sphenopalatine block and BOTOX for chronic migraine relief

  This study is testing whether a nerve block or BOTOX injections can help people with chronic migraines feel better.

  Recruiting Cairo University · Cairo · NCT06974617

• Using Atogepant tablets to prevent migraines in teens aged 12 to 17

  This study is testing if Atogepant tablets can help prevent migraines in teenagers aged 12 to 17.

  Recruiting at 61 sites Phase 3 AbbVie · Huntsville, Alabama and 65 other locations · NCT06810505

• Acceptance and Commitment Therapy to reduce disability in adults with chronic migraine

  This trial will test whether adding Acceptance and Commitment Therapy (ACT) to usual care helps adults with chronic migraine improve daily functioning and reduce headache frequency and pain.

  Recruiting Brigham and Women's Hospital · Boston, Massachusetts · NCT06795867

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.